In this webinar, Cem Baydar and Paul Verdin from Evaluate will sit down with Ali Pashazadeh, Max Baumann, and Mark Mayhew from Treehill Partners to unpick the state of play and look for smart ways to get investment and deals moving as we head into 2023.
Pipeline pitfalls to avoid:
- The latest IPO, M&A, and share price data and how this impacts the industry.
- What's holding things up and who might have to blink first in making deals big pharma or small biotech?
- What creative approaches are dealmakers using to make deals more palatable for players on both sides of the table?